Table 3 Clinical, demographic, and patient self-reported associations with the (natural log-transformed) Monocyte-lymphocyte Ratio

Age (yrs)

0.051

0.019, 0.082

0.002

0.057

0.028, 0.086

< 0.001

Disease Duration (yrs)

0.043

0.013, 0.072

0.004

0.033

0.000, 0.065

0.049

 • Female

–

–

–

–

–

–

 • Male

0.163

0.090, 0.237

< 0.001

0.160

0.092, 0.229

< 0.001

 • No

–

–

–

–

–

–

 • Yes

−0.002

−0.074, 0.070

0.958

0.003

−0.063, 0.069

0.937

BMI

−0.031

−0.066, 0.003

0.074

−0.024

− 0.056, 0.007

0.132

 • Untreated

–

–

–

–

–

–

 • Interferon-β

0.068

0.004, 0.132

0.038

0.077

0.013, 0.140

0.018

 • Cyclophosphamide

0.296

0.187, 0.406

< 0.001

0.310

0.201, 0.418

< 0.001

 • Fingolimod

1.219

0.970, 1.469

< 0.001

1.207

0.959, 1.454

< 0.001

 • Glatiramer Acetate

−0.045

−0.142, 0.052

0.360

−0.047

−0.142, 0.049

0.339

 • Mycophenolate

0.062

−0.037, 0.162

0.219

0.063

−0.035, 0.162

0.206

 • Natalizumab

−0.378

−0.486, − 0.270

< 0.001

−0.374

− 0.48, − 0.267

< 0.001

 • Other

0.057

− 0.063, 0.178

0.350

0.048

−0.071, 0.168

0.426

CES-D

0.010

−0.015, 0.034

0.437

0.007

−0.016, 0.030

0.534

MFIS

0.008

−0.022, 0.038

0.604

0.005

−0.022, 0.033

0.704

MSSS

0.007

−0.019, 0.033

0.604

0.006

−0.018, 0.031

0.611

SF-36 Physical QOL

−0.017

−0.045, 0.012

0.254

−0.011

− 0.038, 0.016

0.441

SF-36 Mental QOL

−0.005

−0.030, 0.019

0.676

−0.005

− 0.027, 0.018

0.678